γ-Diketone neuropathy: axon atrophy and the role of cytoskeletal protein adduction

2004 ◽  
Vol 199 (1) ◽  
pp. 20-34 ◽  
Author(s):  
Richard M LoPachin ◽  
Anthony P DeCaprio
1989 ◽  
Vol 109 (6) ◽  
pp. 2917-2927 ◽  
Author(s):  
P Jones ◽  
P Jackson ◽  
G J Price ◽  
B Patel ◽  
V Ohanion ◽  
...  

Binding of the cytoskeletal protein vinculin to talin is one of a number of interactions involved in linking F-actin to cell-matrix junctions. To identify the talin binding domain in vinculin, we expressed the NH2-terminal region of the molecule encoded by two closely similar, but distinct vinculin cDNAs, using an in vitro transcription translation system. The 5' Eco RI-Bam HI fragment of a partial 2.89-kb vinculin cDNA encodes a 45-kD polypeptide containing the first 398 amino acids of the molecule. The equivalent restriction enzyme fragment of a second vinculin cDNA (cVin5) lacks nucleotides 746-867, and encodes a 41-kD polypeptide missing amino acids 167-207. The radiolabeled 45-kD vinculin polypeptide bound to microtiter wells coated with talin, but not BSA, and binding was inhibited by unlabeled vinculin. In contrast, the 41-kD vinculin polypeptide was devoid of talin binding activity. The role of residues 167-207 in talin binding was further analyzed by making a series of deletions spanning this region, each deletion of seven amino acids contiguous with the next. Loss of residues 167-173, 174-180, 181-187, 188-194, or 195-201 resulted in a marked reduction in talin binding activity, although loss of residues 202-208 had much less effect. When the 45-kD vinculin polypeptide was expressed in Cos cells, it localized to cell matrix junctions, whereas the 41-kD polypeptide, lacking residues 167-207, was unable to do so. Interestingly, some deletion mutants with reduced ability to bind talin in vitro, were still able to localize to cell matrix junctions.


1998 ◽  
Vol 275 (4) ◽  
pp. L788-L799 ◽  
Author(s):  
Alexander D. Verin ◽  
Clare Cooke ◽  
Maria Herenyiova ◽  
Carolyn E. Patterson ◽  
Joe G. N. Garcia

Thrombin-induced Ca2+mobilization, activation of Ca2+/calmodulin-dependent myosin light chain (MLC) kinase (MLCK), and increased phosphorylation of MLCs precede and are critical to endothelial cell (EC) barrier dysfunction. Net MLC dephosphorylation after thrombin is nearly complete by 60 min and involves type 1 phosphatase (PPase 1) activity. We now report that thrombin does not alter total PPase 1 activity in EC homogenates but rather decreases myosin-associated PPase 1 activity. The PPase 1 inhibitor calyculin fails to prevent thrombin-induced MLC dephosphorylation. However, thrombin significantly increased the activity of Ca2+-dependent PPase 2B in EC homogenates (∼1.5- to 2-fold), with PPase 2B activation correlating with phosphorylation of the PPase 2B catalytic subunit. Western immunoblotting revealed PPase 2B to be present in cytoskeletal EC fractions, with specific PPase 2B inhibitors such as cyclosporin (200 nM) and deltamethrin (100 nM to 1 μM) attenuating thrombin-induced cytoskeletal protein dephosphorylation, including EC MLC dephosphorylation. These results suggest a model whereby thrombin-inducible contraction is determined by the phosphorylation status of EC MLC regulated by the balance between EC MLCK, PPase 1 (constitutive), and PPase 2B (inducible) activities.


2000 ◽  
Vol 11 (1) ◽  
pp. 14 ◽  
Author(s):  
Martin Sattler ◽  
Evan Pisick ◽  
Paul T. Morrison ◽  
Ravi Salgia
Keyword(s):  

Toxics ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 98
Author(s):  
Peter S. Spencer ◽  
Xiao Chen

The peripheral (axonal) neuropathy associated with repeated exposure to aliphatic and aromatic solvents that form protein-reactive γ-diketones shares some clinical and neuropathological features with certain metabolic neuropathies, including type-II diabetic neuropathy and uremic neuropathy, and with the largely sub-clinical nerve damage associated with old age. These conditions may be linked by metabolites that adduct and cross-link neuroproteins required for the maintenance of axonal transport and nerve fiber integrity in the peripheral and central nervous system.


2019 ◽  
Author(s):  
Karla P. García-Pelagio ◽  
Atum M. Buo ◽  
Ling Chen ◽  
Megan Moorer ◽  
Joseph P. Stains ◽  
...  

PROTEOMICS ◽  
2013 ◽  
Vol 13 (1) ◽  
pp. 75-88 ◽  
Author(s):  
Christine Veith ◽  
Sigrid Schmitt ◽  
Florian Veit ◽  
Bhola Kumar Dahal ◽  
Jochen Wilhelm ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document